

DAY 1: SUNDAY, 17 NOVEMBER 2013
0900 – 1600 REGISTRATION
1330 – 1800 PRE-CONFERENCE INTERNATIONAL SYMPOSIUM ON NUCLEAR CARDIOLOGY
(Auditorium, St. Luke's Medical Center, Global City)

1330 – 1345 Welcome Address
1345 – 1525 SCIENTIFIC SESSION 1: NUCLEAR CARDIOLOGY I
(Auditorium, St. Luke's Medical Center, Global City)

Session Chairs

- Prof Henry Bom, Nuclear Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea**
- Dr Jerry Obaldo, Division of Nuclear Medicine, Philippine Heart Center, Quezon City, Philippines**

1345 – 1410 Imaging in Non Acute Chest Pain: Choosing The Right Test
PC-01 Dr Pushan Bharadwaj, Nuclear Medicine and PET, Apollo Gleneagles Hospital, Kolkata, India

1410 – 1435 The Challenge of Diagnosing Coronary Heart Diseases in Women. The Special Role of ECG-Gated SPECT Myocardial Scintigraphy
PC-02 Prof Izak Garty, Nuclear Medicine, Central Emek Hospital, Afula, Israel

1435 – 1500 Reporting of Gated MPI
PC-03 Dr Jerry Obaldo, Division of Nuclear Medicine, Philippine Heart Center, Quezon City, Philippines

1500 – 1525 Artifacts and Pitfalls in Myocardial Perfusion SPECT Imaging
PC-04 Dr Qaisar Hussain Siraj, Nuclear Medicine, Farwania Hospital Kuwait, Kuwait

1525 – 1555 COFFEE & TEA BREAK
1555 – 1800 SCIENTIFIC SESSION 2: NUCLEAR CARDIOLOGY II
(Auditorium, St. Luke's Medical Center, Global City)

Session Chairs

- Dr Qaisar Hussain Siraj, Nuclear Medicine, Farwania Hospital Kuwait, Kuwait**
- Dr Teofilo O.L. San Luis, Jr, Nuclear Medicine, St. Luke's Medical Center, Quezon City, Philippines**

1555 – 1620 Role of Nuclear Cardiology in Cardiac Resynchronization Therapy
PC-05 Dr Felix Keng, Nuclear Cardiology, National Heart Centre, Singapore

1620 – 1635 Regional Myocardial Blood Flow Quantification Using Dynamic SPECT: A Clinical Study
PC-06 Dr Uttam Shrestha, Biomedical Imaging, University of California, San Francisco, USA

1635 – 1650 Construction of A Respiratory Phantom to Study SPECT MPI Under The Influence of Respiratory Motion
PC-07 Dr Yiannis Parpottas, Frederick Research Center and Frederick University, Nicosia, Cyprus

1650 – 1710 SPECT MPI Mechanical Phantom with Cardiac and Respiratory Motion: First Results in Clinical Settings
PC-08 Dr Ourania Demetriadou, Nuclear Medicine, Limassol General Hospital, Limassol, Cyprus

1710 – 1800 Interactive Case-based Discussion
Dr Edward-Bengie Magsombol, Philippines

1900 – 2230 WELCOME DINNER
(Grand Sunset Pavilion, Sofitel Philippine Plaza Manila)

2230 END OF DAY 1

DAY 2: MONDAY, 18 NOVEMBER 2013
0800 – 1600 REGISTRATION
0830 – 0915 OPENING CEREMONY
(Luzon Ballroom, Lobby Level)

0830 – 0835 Welcome Address
Dr Emerita Barrenechea, Local Organising Chairman, ICRT 2013

0835 – 0840 Opening Remarks
Prof Richard P Baum, President, WARMTH

0840 – 0910 Tribute to Prof Ajit Padhy
0910 – 0915 WARMTH Candle Lighting Ceremony
0915 – 1100 CONCURRENT SESSIONS
SCIENTIFIC SESSION 3: THYROID I / ORAL PRESENTATIONS
0915 – 1100 SCIENTIFIC SESSION 3: THYROID I
(Luzon Ballroom, Lobby Level)

Session Chairs

1. Prof Harvey Turner, Nuclear Medicine, Fremantle Hospital, Fremantle, Australia
2. Dr Suresh C Srivastava, Medical Isotope Research and Production Program, Brookhaven National Laboratory, New York, USA

0915 – 0935 S-01 Present State of Nuclear Medicine Practice in Japan with Emphasis on Radiopharmaceutical Therapy
Prof Yasuhito Sasaki, Clinical Research Center, Shonankamakura General Hospital, Kamakura, Japan

0935 – 1000 S-02 Updates in the Management of Graves' Disease
Dr Wai Yin Wong, Nuclear Medicine & PET, Singapore General Hospital, Singapore

1000 – 1020 S-03 Recent Advances in the Management of Thyroid Cancer
A/Prof Nemencio Jr Nicodemus, Biochemistry and Molecular Biology, University of the Philippines, College of Medicine, Philippines

1020 – 1040 S-04 Radioiodine Therapy Protocols Revisited: Patient Preparations and Medications During Therapy
Dr Ana Ugrinska, Institute of Pathophysiology and Nuclear Medicine, Medical Faculty, UKIM, Skopje, Republic of Macedonia

1040 – 1100 S-05 Thyroid Remnant Ablation Using 1,110 MBq of I-131 for Outpatients with Thyroid Cancer in Japan
Prof Naoyuki Watanabe, Radiological Sciences, Gunma Prefectural College of Human Health, Maebashi, Japan

DAY 2: MONDAY, 18 NOVEMBER 2013

(continued)

0930 – 1100	ORAL PRESENTATIONS (Mindoro Room, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> 1. Dr Ruben Ogbac, Nuclear Medicine, St Luke's Medical Center, Quezon City, Philippines 2. Dr Sze Ting Lee, Nuclear Medicine & Centre for PET, Austin Health, Victoria, Australia
0930 – 0945	Newer Pretargetting Techniques For Radiobioconjugate Therapy Prof Daya Kishore Hazra, Nuclear Medicine, Boston Medical Centre, Agra, India
0945 – 1000	Differentiated Thyroid Carcinoma in Young Patients Treated with I-131: Recurrent Disease and Outcome A/Prof Marina Vljakovic, Nuclear Medicine, Clinical Center Nis, Nis, Serbia
1000 – 1015	Level of Thyroglobulin (Tg) in Patients with Papillary Thyroid Carcinoma (PTC) Received Radio Iodine (RAI) Ablation Therapy Dr Savvas Frangos, Nuclear Medicine, Bank of Cyprus Oncology Center, Strovolos- Nicosia, Cyprus
1015 – 1030	Well-Differentiated Thyroid Carcinoma of Childhood And Adolescence – A Long Term Experience at A Single Institute Dr Faria Nasreen, Nuclear Medicine, Institute of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh
1030 – 1045	Sensitivity of Preparation with rhTSH or Thyroid Hormone Withdrawal Using 131I Whole Body Scans to Identify Metastases of Differentiated Thyroid Cancer Dr Knut Liepe, Nuclear Medicine, GH Kassel, Kassel, Germany
1045 – 1100	Click Chemistry For Design of Oncopharmaceuticals For Theragnostics: Radiolabels For Imaging and Therapy, Nonradioactive Labels For Imaging A/Prof Padmamalika Hazra, Chemistry, St Johns College, Agra, India
1100 – 1130	COFFEE & TEA BREAK / TRADE EXHIBITION (Pre-Function Area / Visayas Ballroom, Lobby Level)
1100 – 1130	POSTER PRESENTATIONS (Pre-Function Area / Visayas Ballroom, Lobby Level)
P-01	Dual-Phase Tc99m MIBI Scintigraphy in Lymphoma as a Predictor of Response to Chemotherapy Z. Chiragh, et al (Pakistan)
P-02	Post Synthesis of a new [64Cu]- Porphyrin Complex on Silica MCM-41 as a New Radiopharmaceutical Delivery System Y Fazaeli, et al (Iran)
P-03	Radio Synthesis of a New [201Tl]- Porphyrin Complex as an Imaging Agent Y Fazaeli, et al (Iran)
P-04	Indium-111 Maltolate Complex as a Cell Labeling Agent for SPECT Imaging Y Fazaeli, et al (Iran)
P-05	SPECT Imaging of Blood Pool in Rabbits, Using PEG-Nano Liposomes Labeled with 99mTc-HMPAO K Sadri, et al (Iran)

DAY 2: MONDAY, 18 NOVEMBER 2013
(continued)

P-06	Prognostic Value of FDG Uptake of Primary Tumor and Metastatic Lesions in Advanced Non-Small Cell Lung Cancer XC Nguyen, et al (Vietnam)
P-07	Feasibility Study for Neodymium-140 (140Nd) Radioisotope Production and its Purification Using Nano-resin M Aboudzadeh, et al (Iran)
P-08	Production of Industrial Zinc-62/Copper-62 Generator for PET Purposes Y Fazaeli, et al (Iran)
P-09	Radioiodine Ablation of Thyroid Remnants in Patients with Differentiated Thyroid Carcinoma SR Miah, et al (Bangladesh)
P-10	Preparation of 99mTc-labeled methotrexate by a Direct Labeling Technique as a Potential Diagnostic and Response Monitoring Agent for Breast Cancer Rashid Rasheed, et al (Pakistan)
P-11	Bone Metastasis from Differentiated Thyroid Carcinoma: Diagnosis, Treatment And Outcome Experience of A Tunisian Centre K Chatti, et al (Tunisia)
P-12	Effectiveness and Thyroid Functional Status after Radioiodine Therapy for Thyrotoxicosis – A Retrospective Study M Hossain, et al (Bangladesh)
P-13	Details Of Histopathology in Patients with One or More First Degree Relatives who have Well Differentiated Thyroid Cancer (WDTC) S Frangos, et al (Cyprus)
P-14	Utility of 99mTc HYNIC–TOC in evaluation of Neuroendocrine Tumor (NET): A Pictorial Review A Shinto, et al (India)
1130 – 1300	SCIENTIFIC SESSION 4: THYROID II & RADIOPHARMACY, DOSIMETRY, RADIOLOGICAL AND NUCLEAR EMERGENCY (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> Prof Naoyuki Watanabe, Radiological Sciences, Gunma Prefectural College of Human Health, Maebashi, Japan A/Prof Cecilia Jimeno, Medicine Section of Endocrinology & Diabetes, Philippine General Hospital, Manila, Philippines
1130 – 1155 S-09	To Ablate or Not To Ablate: An Evidence Based Approach Dr Savvas Frangos, Nuclear Medicine, Bank of Cyprus Oncology Center, Strovolos- Nicosia, Cyprus
1155 – 1215 S-07	An Overview of Our Specially-Developed Online Remote Radiation Monitoring System for Patients with Differentiated Thyroid Carcinoma Treated with Radioiodine Prof Milovan Matovic, Nuclear Medicine, Clinical Center Kragujevac, Kragujevac, Serbia
1215 – 1240	Tyrosine Kinase Therapy in Patients Refractory to Radioiodine Dr Haluk B Sayman, Nuclear Medicine, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey
1240 – 1300 S-29	Alpha-Therapy: Which Radionuclide, Which Carrier Molecule, Which Clinical Indication? Prof Jean-Francois Chatal, Arronax Cyclotron, GIP Arronax, Nantes-Saint-Herblain, France

DAY 2: MONDAY, 18 NOVEMBER 2013
(continued)

1300 – 1400	LUNCH SYMPOSIUM (SPONSORED BY GENZYME, A SANOFI COMPANY) (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Center, Quezon City, Philippines Dr Partha S Choudhury, Nuclear Medicine, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India
1315 – 1345 S-10	Radioiodine for Thyroid Cancer: Less is More Findings from A Multicenter, Randomized Non-Inferiority Trial and Its Applicability in Practice Dr B K Yap, Clinical Oncology, The Christie NHS Trust, Manchester, United Kingdom
1400 – 1520	SCIENTIFIC SESSION 5: MOLECULAR IMAGING IN THERAPEUTIC NUCLEAR MEDICINE I (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> Dr Savvas Frangos, Nuclear Medicine, Bank of Cyprus Oncology Center, Strovolos- Nicosia, Cyprus Dr Gopinath Gnanasegaran, Nuclear Medicine, Guy's & St Thomas Hospital NHS Foundation Trust, London, United Kingdom
1400 – 1420 S-11	The Ups-And-Downs of MIBG; A Historical Perspective Dr Cornelis Hoefnagel, Nuclear Medicine, AvL-NKI, Badhoevedorp, The Netherlands
1420 – 1440 S-12	SPECT-CT in Post Therapy Imaging Prof John Buscombe, Nuclear Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom
1440 – 1500 S-14	Role of PET/CT in Radiotherapy Planning Dr Sze Ting Lee, Nuclear Medicine & Centre for PET, Austin Health, Victoria, Australia
1500 – 1520 S-08	Recent Advances in the Imaging and Therapy of Active Atheromatous Disease Using Theragnostic High-LET Electron Emitters Dr Suresh C Srivastava, Medical Isotope Research and Production Program, Brookhaven National Laboratory, New York, USA
1520 – 1545	COFFEE & TEA BREAK / TRADE EXHIBITION / POSTER VIEWING (Pre-Function Area / Visayas Ballroom, Lobby Level)

DAY 2: MONDAY, 18 NOVEMBER 2013

(continued)

1520 – 1545

POSTER PRESENTATIONS

(Pre-Function Area / Visayas Ballroom, Lobby Level)

Session
Coordinator

Dr Michele Ogbac, Nuclear Medicine, Philippine Heart Center, Quezon City, Philippines

- | | |
|------|---|
| P-15 | Biodistribution Imaging Study in Rats after Intra-articular Administration of ⁹⁰Y-Labeled Tin Fluoride Colloid
L Jaukovic, et al (Serbia) |
| P-16 | I-131 Capsule versus Liquid: A Comparative Study and Clinical Usefulness in Thyroid carcinoma patient. Quantitative and Dosimetric Evaluation
Om Prakash, et al (India) |
| P-17 | Perspectives of Availability of Therapeutic Radioisotopes
VR Hernan, et al (Bolivia) |
| P-18 | Life Quality Evaluation in Patients with Differentiated Thyroid Cancer: Is SF-36 Appropriate for this Purpose?
NK Ayati, et al (Iran) |
| P-19 | Thyroid Volume Changes on Ultrasonography as A Predictor of Radioiodine Therapy Outcome in Hyperthyroidism
NK Ayati, et al (Iran) |
| P-20 | Undesirable Effects after Remnant Ablation with Radioactive Iodine in Patients with Differentiated Thyroid Carcinoma – Our Experience
M Agolti, et al (Argentina) |
| P-21 | Experimental Study of Targeting Glioma with ¹³¹I-CH12 McAb
P Li, et al (China) |
| P-22 | Expansion of Radionuclide Therapy in a Developing Country: Experience of Bangladesh
Mizanul Hasan (Bangladesh) |
| P-23 | Value of Baseline Thyroglobulin Level in Post-Thyroidectomy Patients with Differentiated Thyroid Cancer
FAH Hussain, et al (Bangladesh) |
| P-24 | The Most Common Complaints of Thyroid Cancer Patients Post-Thyroidectomy and Radioiodine Therapy (A Preliminary Report)
S Shafiei, et al (Iran) |
| P-25 | Accuracy Study of Sentinel Node Biopsy by ^{99m}Tc Phytate in Patients with Non-Small Cell Lung Carcinoma (A Preliminary Report)
S Shafiei, et al (Iran) |
| P-26 | Characteristics of Differentiated Thyroid Carcinoma Patients with Low Serum Thyroglobulin-off level but Positive Post-therapy ¹³¹I -WBS in First Six Months Follow-Up
D Yulistiawaty (Indonesia) |
| P-27 | Remnant Ablation using 1 GBq (30 mCi) I-131 in High Risk Differentiated Thyroid Carcinoma Patients
Fithriany S, et al (Indonesia) |
| P-28 | Clinical Significance of Thyroglobulin Antibody Pattern in Patients with Differentiated Thyroid Carcinoma
F Hutomo, et al (Indonesia) |

DAY 2: MONDAY, 18 NOVEMBER 2013
(continued)

1545 – 1750	CONCURRENT SESSIONS SCIENTIFIC SESSION 6: MOLECULAR IMAGING IN THERAPEUTIC NUCLEAR MEDICINE II / WARMTH GOVERNING BODY MEETING (GOVERNING BODY MEMBERS ONLY)
1545 – 1800	SCIENTIFIC SESSION 6: MOLECULAR IMAGING IN THERAPEUTIC NUCLEAR MEDICINE II (Luzon Ballroom, Lobby Level)
Session Chairs	1. Dr Aviral Singh, Intensive Care Medicine, The Canberra Hospital, Canberra, Australia 2. Dr Jonas Francisco Santiago, Nuclear Medicine, St. Luke's Medical Center, Taguig, Philippines
1545 – 1610 S-15	Choline PET/CT in Staging and Restaging at Biochemical Recurrence for Prostate Cancer: A Systematic Review and A Meta-Analysis of Cohort Studies (Approx. 6000 Patients) Prof Kalevi Kairemo, Molecular Radiotherapy & Nuclear Medicine, Docrates Cancer Center, Helsinki, Finland
1610 – 1635 S-17	Alpha Therapy and PET/SPECT Imaging of Metastatic Bone Disease Prof Homer A. Macapinlac, Nuclear Medicine, UT M. D. Anderson Cancer Center, Houston, USA
1635 – 1700 S-18	Molecular Imaging of Neuroendocrine Tumours A/Prof Grzegorz Kaminski, Endocrinology & Radioisotope Therapy, Military Institute of Medicine, Warsaw, Poland
1700 – 1725 S-20	SIRT: A Decade of Experience Prof Adil Al-Nahhas, Nuclear Medicine, Hammersmith Hospital/ Imperial College, London, United Kingdom
1725 – 1800	Radionuclide Therapy Quiz Dr Gopinath Gnanasegaran, Nuclear Medicine, Guy's & St Thomas Hospital NHS Foundation Trust, London, United Kingdom Prof Kavitha Nallapareddy, Nuclear Medicine, Nizams Institute of Medical Sciences, Hyderabad, India
1600 – 1730	WARMTH GOVERNING BODY MEETING (GOVERNING BODY MEMBERS ONLY) (Mindoro Room, Lobby Level)
1900 – 2300	GALA DINNER (Luzon Ballroom, Lobby Level)
	<ul style="list-style-type: none"> ▪ WARMTH Awards ▪ Gala Dinner ▪ Entertainment
2300	END OF DAY 2

DAY 3: TUESDAY, 19 NOVEMBER 2013
0830 – 1100 CONCURRENT SESSIONS
SCIENTIFIC SESSION 7: NEURO-ENDOCRINE TUMOURS I / ORAL PRESENTATIONS
0830 – 1100 SCIENTIFIC SESSION 7: NEURO-ENDOCRINE TUMOURS I

(Luzon Ballroom, Lobby Level)

- Session Chairs**
- 1. Prof John Buscombe, Nuclear Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom**
 - 2. A/Prof Nemencio Jr Nicodemus, Biochemistry and Molecular Biology, University of the Philippines, College of Medicine, Philippines**

0830 – 0855 S-21 PRRT of Neuroendocrine Neoplasms (NEN) – The Bad Berka Experience after More than 4,000 Treatment Cycles in NEN Patients

Prof Richard P Baum, THERANOSTICS Center for Molecular Imaging and Therapy, Zentralklinik Bad Berka, Bad Berka, Germany

0855 – 0920 S-22 Design of An International Multicentre Randomised Controlled Phase II Clinical Trial of 177Lu-Octreotate/Capecitabine/Temozolomide, Radiopeptide Chemotherapy of Gastro-Entero-Pancreatic Neuroendocrine Tumours: The CONTROL – NET Study

Prof Harvey Turner, Nuclear Medicine, Fremantle Hospital, Fremantle, Australia

0920 – 0945 S-23 Targeting Tumor Heterogeneity to Improve Outcomes of Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumours

A/Prof Michael Hofman, Medicine, University of Melbourne, Melbourne, Australia

0945 – 1010 S-24 Quality of Life: From a Patient Perspective

Mr William Claxton, Carcinoid & Neuroendocrine Tumor Society, Singapore

1010 – 1035 S-25 Nuclear Medicine: A Patient's Viewpoint – Understanding Patient Education / Advocacy

Mr Josh Mailman, NorCal CarciNET Community, Oakland, CA USA

1035 – 1100 S-26 Long Term Efficacy of i.v. and i.a. PRRT using 90Y or 177Lu in Patients with NET

Dr Jaroslaw Cwikla, Radiology and Diagnostic Imaging, Postgraduate Medical Centre and Central Clinical Hospital, Warsaw, Poland

DAY 3: TUESDAY, 19 NOVEMBER 2013
(continued)
0915 – 1100 ORAL PRESENTATIONS
(Mindoro Room, Lobby Level)

Session Chairs

1. **Dr Vincent Peter Magboo, Nuclear Medicine, St. Luke's Medical Center, Quezon City, Philippines**
2. **Dr Partha S Choudhury, Nuclear Medicine, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India**

0915 – 0930 **Development of A New [140Nd]-Porphyrin Complex as A Possible Tumor Imaging Agent**
Dr Mohammad Reza Aboudzadeh Rovais, Nuclear Medicine, Agricultural, Medical and Industrial Research School, Karaj, Iran

0930 – 0945 **Five Year Experience of Strontium-90 Irradiation for Treatment of Post-Operative Conjunctival Squamous Cell Carcinoma**
Prof Raihan Hussain, Nuclear Cardiology, Institute of Nuclear Medicine and Ultrasound, Dhaka, Bangladesh

0945 – 1000 **Prospective Study of Skeletal Related Events (SREs) Incidence in Patients whom Radionuclide Therapy was added for Bone Metastases and Primary Tumor's Treatment**
Dr Nigora Rasulova, Nuclear Medicine, Republic Specialized Center of Surgery, Tashkent, Uzbekistan

1000 – 1015 **Development of New Potential Multiple Myeloma Theragnostic Agents**
~~Dr Juan Pablo Gambini, Centro de Medicina Nuclear, Hospital de Clinicas, Montevideo, Uruguay~~

1015 – 1030 **Customization of 90Y- SIR Sphere Delivery Set: Technical Modifications in Our Institution Leading to Improved Radiation Safety and Logistics**
Dr Ashish Kumar Jha, Nuclear Medicine & Molecular Imaging, Tata Memorial Hospital, Mumbai, India

1030 – 1045 **Radiosynoviorthesis (RSO) in Joints Less Frequently Affected with Arthropathy after the Failure of Previous Treatment**
Dr Marika Vereb, Nuklearmedizin, Klinikum Kassel, Kassel, Germany

1045 – 1100 **¹⁸⁸Re-Zoledronic Acid: First-In-Man Study**
Ms Kochetova Tatiana, Radionuclide Therapy, Medical Radiology Research Center, Obninsk, Russia

1100 – 1130 COFFEE & TEA BREAK / TRADE EXHIBITION / POSTER VIEWING
(Pre-Function Area / Visayas Ballroom, Lobby Level)

DAY 3: TUESDAY, 19 NOVEMBER 2013

(continued)

1100 – 1130 POSTER PRESENTATIONS (Pre-Function Area / Visayas Ballroom, Lobby Level)	
Session Coordinator	Dr Marie Rhiamar Sauler-Gomez, Radiology / Section of Nuclear Medicine, De La Salle University Medical Center, Cavite, Cavite
P-29	Role of Dual Point 18F-FDG PET/CT Imaging in Assessment of Micrometastases in Breast Cancer Patients MK Srivastava, et al (India)
P-30	Radionuclide Therapy Modalities: Local Experience in Nuclear Medicine Department of MRCCC – SHS ID Mulyanto, et al (Indonesia)
P-31	Case Study: First Experience in I-131 MIBG Palliative Therapy for Refractory Neuroblastoma Patients R Yudistiro, et al (Indonesia)
P-32	The Benefits of Adjuvant 131I Therapy for Differentiated Thyroid Carcinoma with Elevated Thyroglobulin and Negative 131I Whole body Scan L Herawati Diah, et al (Indonesia)
P-33	In Vivo SPECT Imaging and Biological Evaluation of 198,199Au-labeled Graphene Oxide Nanoflakes as Therapeutic Agents Y Fazaeli, et al (Iran)
P-34	Bone Lesion Score – A Predictor of Success of Radionuclide Therapy in Skeletal Metastasis G Jameel, et al (Pakistan)
P-35	Patient Characteristics and Outcomes of Radioiodine Therapy in Differentiated Thyroid Cancer with Ineffective TSH-Stimulation: A Case Series AR Dewi, et al (Indonesia)
P-36	Nuclear Medicine - Ethical Issues in Current Practices S Fatima, et al (Pakistan)
P-37	Value of Tl-201 Imaging in Predicting Therapeutic I-131 Uptake in Patients with Thyroglobulin-Positive But I-131 Scan Negative in Differentiated Thyroid Cancer D Tumapon, et al (Philippines)
P-38	PNRI Pioneering Local Production of Molybdenum-99/Techetium-99m (Mo-99/Tc-99m) Generators for Nuclear Medicine Centers in the Philippines A Bulos, et al (Philippines)
P-39	Development of A Novel Porphyrin Complex As An Imaging Agent: [67Ga]-3,4 Dimethoxylated Porphyrin Y Fazaeli, et al (Iran)
P-40	Nanopurification and Quality Control of [64Cu] CuCl₂ by Amino Functionalized Fe₃O₄ Magnetic Nano-Particles Yousef Fazaeli, et al (Iran)
P-41	Radioiodine Therapy in Differentiated Thyroid Carcinoma – Long Term Follow-Up M Hoque, et al (Bangladesh)
P-42	Radiosynthesis, Quality Control and Biological Evaluation Of [111In] 5, 10, 15, 20-Tetra Phenyl Porphyrin Complex in Rats Bearing Breast Tumors As A Possible Imaging/PDT Agent Yousef Fazaeli (Iran)

DAY 3: TUESDAY, 19 NOVEMBER 2013
(continued)

1130 – 1305	SCIENTIFIC SESSION 8: NEUROENDOCRINE TUMOURS II, LYMPHOMA & MISCELLANEOUS (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> 1. Prof Hans Biersack, Nuclear Medicine, University Hospital Bonn, Bonn, Germany 2. Dr Charity Viado-Gorospe, Philippines
1130 – 1150 S-27	68Ga-DOTATOC PET/CT in Patients with Carcinoma of Unknown Primary of Neuroendocrine Origin: Impact on Patient Management Prof Omar Alonso, Nuclear Medicine, Clinical Hospital, University of Uruguay, Montevideo, Uruguay
1150 – 1210 S-28	Sr-89 Bremsstrahlung SPECT Imaging Using SPECT/CT System in Bone Metastases for Theranostics Strategy Prof Hiroshi Toyama, Radiology, Fujita Health University, Toyoake, Japan
1210 – 1230	PET Monitoring in Treatment Response Dr Greg Wiseman, Nuclear Medicine / Radiology, Mayo Clinic, Minnesota, USA
1230 – 1250 S-30	First-Line Outpatient Radioimmunotherapy of Follicular Non-Hodgkin Lymphoma With ¹³¹I-Rituximab in 100 Patients Followed Up to 5 Years Prof Harvey Turner, Nuclear Medicine, Fremantle Hospital, Fremantle, Australia
1250 – 1305 S-31	Selection for PRRT in Neuroendocrine Tumours: Which Patients Should We Treat and Which Radionuclide Should We Use? Dr Shaunak Navalkisoor, Nuclear Medicine, Royal Free London NHS Foundation Trust, London, United Kingdom
1305 – 1400	LUNCH SYMPOSIUM (SPONSORED BY GE HEALTHCARE) (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> 1. Dr Sze Ting Lee, Nuclear Medicine & Centre for PET, Austin Health, Victoria, Australia 2. Dr Maria Lourdes Taylan, Nuclear Medicine, University of St. Thomas Hospital, Manila, Philippines
1315 – 1345 S-32	A Vision Beyond Mammography Dr Antonio C. Garcia, Nuclear Medicine, Manila Doctors Hospital, Manila, Philippines
1400 – 1515	SCIENTIFIC SESSION 9: PROSTATE CANCER (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> 1. Dr Sze Ting Lee, Nuclear Medicine & Centre for PET, Austin Health, Victoria, Australia 2. Dr Jose Eduardo Rondain, Nuclear Medicine, Makati Medical Center, Makati, Philippines
1400 – 1425 S-33	THERANOSTICS of Prostate Cancer – An Outstanding Opportunity for Nuclear Medicine Prof Richard P Baum, THERANOSTICS Center for Molecular Imaging and Therapy, Zentralklinik Bad Berka, Bad Berka, Germany
1425 – 1450 S-34	Radionuclide Therapy of Refractory Prostate and Breast Cancer Bone Metastases – Improved Survival Prof Hans Biersack, Nuclear Medicine, University Hospital Bonn, Bonn, Germany
1450 – 1515 S-35	Present Status of Radioimmunotherapy of Castrate-Resistant Prostate Cancer with ¹⁷⁷Lu-J591 mAb (ATL101) Prof Jean-Francois Chatal, Arronax Cyclotron, GIP Arronax, Nantes-Saint-Herblain, France

DAY 3: TUESDAY, 19 NOVEMBER 2013

(continued)

1515 – 1545	COFFEE & TEA BREAK / TRADE EXHIBITION / POSTER VIEWING (Pre-Function Area / Visayas Ballroom, Lobby Level)
1515 – 1545	POSTER PRESENTATIONS (Pre-Function Area / Visayas Ballroom, Lobby Level)
Session Coordinator	Dr Wenceslao Lauderer, Philippines
P-43	[64Cu]-DOTA-PR81 for PET Applications, The Production and Quality Control B Alirezapour, et al (Iran)
P-44	Value Of Thyroglobulin Measurement in Treatment and Follow Up of Patients with Follicular Differentiated Thyroid Cancer SR Zakavi (Iran)
P-45	Treatment Planning in Radionuclide Therapy H Rajabi (Iran)
P-46	3-Benzyl-3-Hydroxy-1,5-Dimethyl-1,3-Dihydro-Indol-2-One Labeled Gallium-67&68 as Potential Anticancer Agents M Ghandi, et al (Iran)
P-47	Withholding Radioactive Iodine Therapy in Thyroid Cancer Patients – A Drawback H Caldito, et al (Philippines)
P-48	Evaluation of Pharmacokinetics of 188Re-KHEDP and 99mTc-HDP in Human M Smolyarchuk, et al (Russia)
P-49	Evaluation of 188Re-KHEDP (Phosphoren) for Palliative Treatment in Patients with Bone Metastases V Krylov, et al (Russia)
P-50	Determining Differences in Whole Body Radio-iodine Clearance Using Dose Rate Monitoring in Patients Undergoing High-Dose Radioactive Iodine Therapy: A Single Institution Experience A Sunga, et al (Philippines)
P-51	Activity in Urine Following 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy I Vito, et al (United Kingdom)
P-52	Clinical Results of Combined Therapy of Painful Multiple Skeletal Metastases By Samarium-153 Oxabifore Administration and Pamidronate Injection D Arybzhhanov, et al (Kazakhstan)
P-53	Introducing I-131 MIBG Therapy in Pakistan, Steps Taken to Administer First Therapy in A Patient Having Metastatic Pheochromocytoma S Butt, et al (Pakistan)
P-54	AHCC - Impact on The Immunological System on Patients With Disseminated Neuroendocrine Tumors (NETs) After Treatment with The Radioisotope Preparation (90Y-DOTA-TATE) – An Initial Report N Szalus, et al (Poland)
P-55	Follicular Thyroid Cancer Presenting with Skull Metastases without Uptake of Radioiodine : A Case Report A Elliyanti (Indonesia)
P-56	High Vs. Low Dose Radio-Iodine Therapy for Initial Remnant Ablation of Post-Thyroidectomised Patients with Differentiated Thyroid Cancer: A Meta-Analysis J Mendoza, et al (Philippines)

DAY 3: TUESDAY, 19 NOVEMBER 2013
(continued)

1545 – 1705	SCIENTIFIC SESSION 10: ARTHRITIS & RADIOSYNOVECTOMY (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> Dr Knut Liepe, Nuclear Medicine, GH Kassel, Kassel, Germany Dr Juan Javier Lichauco, Philippines
1545 – 1610 S-36	Radiation Synovectomy: Overview Prof Gynter Moedder, German Centre for Radiosynoviorthesis, Cologne, Germany
1610 – 1630 S-37	Recent Advances in the Management of Inflammatory Arthritis A/Prof Michael L Tee, Physiology / Internal Medicine-Rheumatology, University of the Philippines College of Medicine, Manila, Philippines
1630 – 1645 S-38	Current Status of Radiosynovectomy in India – Problems & Solutions Prof Birendra Kishore Das, Nuclear Medicine, Utkal Institute of Medical Sciences, Bhubaneswar, India
1645 – 1705	Clinical Aspects of Radiosynovectomy: An Update Dr Knut Liepe, Nuclear Medicine, GH Kassel, Kassel, Germany
1830 – 2200	OENOPHILOUS DINNER (Casa Roces) *Transport will be available from 1745 onwards at Hotel Lobby
2200	END OF DAY 3

DAY 4: WEDNESDAY, 20 NOVEMBER 2013
0900 – 1100 SCIENTIFIC SESSION 11: NEW THERAPIES

(Luzon Ballroom, Lobby Level)

- Session Chairs**
- 1. Prof Irene Virgolini, Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria**
 - 2. Dr Priscilla Caguioa, Philippines**

0900 – 0925 RIT & EBRT in Lymphoma

S-39 Dr Michael Tomblyn, Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, USA

0925 – 0950 Boron Neutron Captute Therapy (BNCT) of Cancer: A New Type of Radionuclide Therapy

S-40 Prof Jun Hatazawa, Nuclear Medicine, Osaka University, Suita, Japan

0950 – 1015 The Alpha Emitter Alpharadin®: The Treatment of Bone Metastases

S-41 Dr Knut Liepe, Nuclear Medicine, GH Kassel, Kassel, Germany

1010 – 1035 Current and Future IAEA Programs on Radionuclide Therapy

S-42 Prof Adriano Duatti, Nuclear Applications, IAEA, Vienna, Austria

1035 – 1100 Somatostatin Theranostics Beyond Neuroendocrine Tumours

S-43 A/Prof Michael Hofman, Medicine, University of Melbourne, Melbourne, Australia

1100 – 1120 COFFEE & TEA BREAK / TRADE EXHIBITION / POSTER VIEWING

(Pre-Function Area / Visayas Ballroom, Lobby Level)

1100 – 1120 POSTER PRESENTATIONS

(Pre-Function Area / Visayas Ballroom, Lobby Level)

P-57 **Heterogeneity Analysis of [18F]-FDG Uptake in Differentiating Between Metastatic and Inflammatory Lymph Nodes in Adenocarcinoma of The Lung: Comparison with Other Parameters and Its Clinical Application**

H Budiawan, et al (Korea)

P-58 **Radiation Dose Estimates of Technologists in The Positron Emission Tomography (PET) Center At The St. Luke's Medical Center**

J M Dela Cruz (Philippines)

P-59 **Role of Myocardial Perfusion Imaging in Acute Coronary Syndrome**

Dr Imran Abdullah (Pakistan)

P-60 **Role of SPECT-CT in Radiotherapy**

S Sergieva, et al (Bulgaria)

P-61 **The Association of HIV And Skeletal Metastases in Breast Cancer**

Masha Maharaj, et al (South Africa)

P-62 **Tc-99m MIBI Scintigraphy as an Early Predictor of Radioiodine Treatment Response in DTC**

G Gunawan, et al (Indonesia)

P-63 **SNOLL (Sentinel Lymph Node Biopsy and Radioguided Occult Lesion Localisation) in Early Breast Carcinoma – Two Years of Experience in Slovakia**

L Kaliska, et al (Slovakia)

P-64 **Breast Cancer and Autoimmune Thyroiditis: Does the Sodium Iodide Symporter Play A Role?**

Jefferson R. Pagsisihan, et al (South Korea)

P-65 **Novel Method for Cyclotron Production of 45Ti**

M Aboudzadeh, et al (Iran)

DAY 4: WEDNESDAY, 20 NOVEMBER 2013
(continued)

- | | |
|------|---|
| P-66 | Benign Lymphadenopathies on FDG PET/CT: Castleman's Disease, Kikuchi-Fujimoto's Disease and Reactive Lymph Node Hyperplasia
Jamilla Cecilia L. Gomez, et al (Philippines) |
| P-67 | Outcome of Radioiodine Therapy in Benign Nodular Non-Toxic Goiter. A Preliminary Study
Karina Michaela Dela Cruz, et al (Philippines) |
| P-68 | Pleuro-peritoneal Communication Detected by Technetium 99m-tagged Macroaggregated Albumin (MAA) Radionuclide Peritoneal Scintigraphy in a Chronic Kidney Disease Patient on Peritoneal Dialysis: A Case Report
Carla Mari M. Macaisa, et al (Philippines) |
| P-69 | Pre-clinical Dosimetry and Prognosis of Safety and Effectiveness of Radiopharmaceuticals 188Re-zoledronic Acid
Voloznev L.V, et al (Russia) |
| P-70 | The Role of 99mTc Hydroxydiphosphonate (HDP) Scintimammography in the Diagnosis of Breast Cancer
Chris Eduarte, et al (Philippines) |

1120 – 1300 SCIENTIFIC SESSION 12: LIVER THERAPY & MISCELLANEOUS

(Luzon Ballroom, Lobby Level)

Session Chairs

1. **Dr Butch Magsombol, Nuclear Medicine & PET, Singapore General Hospital, Singapore**
2. **Dr Samuel Ang, Philippines**

- | | |
|---------------------|---|
| 1120 – 1150
S-45 | Overview of Y-90 SIRT and Dosimetric Considerations – SGH Experience
Dr David Ng, Nuclear Medicine & PET, Singapore General Hospital, Singapore |
| 1150 – 1210
S-46 | 3D Personalized Monte Carlo Dosimetry for Treatment Planning in 90Y-Microspheres Therapy: Absorbed Dose and Biological Effective Dose Considerations
Ms Alice Petitguillaume, Internal Dosimetry, Institute of Radiation Protection and Nuclear Safety (IRSN), Fontenay-Aux-Roses, France |
| 1210 – 1230
S-47 | Y-90 Microsphere Treatment of Hepatic Neuroendocrine Metastases
Dr James Warrington, Nuclear Medicine, London Health Sciences Centre, London, Canada |
| 1230 – 1250
S-13 | Imaging of Drug Resistant TB Decoded
Prof Mike Sathekge, South Africa |
| 1250 – 1300
S-48 | Radionuclide Clinical Trials
Prof John Buscombe, Nuclear Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom |

1300 – 1400 LUNCH / TRADE EXHIBITION

(Pre-Function Area / Visayas Ballroom, Lobby Level)

DAY 4: WEDNESDAY, 20 NOVEMBER 2013
(continued)

1400 – 1540	SCIENTIFIC SESSION 13: NUCLEAR MEDICINE – TODAY & TOMORROW (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> Prof Richard P Baum, THERANOSTICS Center for Molecular Imaging and Therapy, Zentralklinik Bad Berka, Bad Berka, Germany Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Center, Quezon City, Philippines
1400 – 1430 S-44	Tribute Lecture: Development Experience of Re-188-HDD Lipiodol for Liver Cancer Therapy Prof Jae Min Jeong, Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
1430 – 1450 S-49	A Statistician's Fond Remembrance of Ajit Padhy Prof Janez Stare, Biostatistics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
1450 – 1515 S-50	Nuclear Medicine – I Have Seen It All Prof Yasuhito Sasaki, Clinical Research Center, Shonankamakura General Hospital, Kamakura, Japan
1515 – 1540 S-51	Nuclear Medicine – The Future Prof Irene Virgolini, Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria
1540 – 1600	COFFEE & TEA BREAK / TRADE EXHIBITION (Pre-Function Area / Visayas Ballroom, Lobby Level)
1600 – 1700	WARMTH MEMBERS' ASSEMBLY ALL MEMBERS OF WARMTH TO ATTEND THE MEETING (Luzon Ballroom, Lobby Level)
1700 – 1730	CLOSING CEREMONY
1730	END OF DAY 4

DAY 5: THURSDAY, 21 NOVEMBER 2013
SIGHT-SEEING TOUR
END OF DAY 5